Leerink Partnrs Analysts Lower Earnings Estimates for Danaher Co. (NYSE:DHR)

Danaher Co. (NYSE:DHR) – Research analysts at Leerink Partnrs decreased their Q3 2024 EPS estimates for shares of Danaher in a research note issued on Tuesday, April 23rd. Leerink Partnrs analyst P. Souda now anticipates that the conglomerate will post earnings per share of $1.70 for the quarter, down from their prior estimate of $1.87. The consensus estimate for Danaher’s current full-year earnings is $7.64 per share. Leerink Partnrs also issued estimates for Danaher’s Q4 2024 earnings at $2.42 EPS, FY2024 earnings at $7.60 EPS, Q1 2025 earnings at $2.25 EPS, FY2025 earnings at $8.70 EPS and FY2026 earnings at $9.63 EPS.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same period last year, the firm posted $2.36 EPS. The company’s revenue for the quarter was down 2.6% on a year-over-year basis.

A number of other research analysts also recently issued reports on DHR. Citigroup raised their price target on shares of Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a research report on Wednesday. KeyCorp lifted their price objective on shares of Danaher from $260.00 to $290.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Bank of America lifted their price objective on shares of Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a research report on Wednesday. Robert W. Baird lifted their price objective on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research report on Wednesday. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $270.00.

Danaher Trading Up 0.3 %

Danaher stock opened at $246.45 on Thursday. The firm’s 50-day moving average is $248.87 and its 200-day moving average is $231.08. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.37 and a current ratio of 1.85. Danaher has a 1 year low of $182.09 and a 1 year high of $259.00. The company has a market cap of $182.54 billion, a P/E ratio of 41.77, a PEG ratio of 4.19 and a beta of 0.83.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Cape Investment Advisory Inc. purchased a new position in Danaher during the fourth quarter valued at approximately $25,000. Tsfg LLC grew its position in Danaher by 733.3% during the first quarter. Tsfg LLC now owns 100 shares of the conglomerate’s stock valued at $25,000 after purchasing an additional 88 shares in the last quarter. BKM Wealth Management LLC purchased a new position in Danaher during the fourth quarter valued at approximately $27,000. Wetzel Investment Advisors Inc. purchased a new position in Danaher during the fourth quarter valued at approximately $29,000. Finally, OFI Invest Asset Management purchased a new position in Danaher during the third quarter valued at approximately $30,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Danaher

In other news, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the transaction, the chief executive officer now owns 115,995 shares of the company’s stock, valued at approximately $28,908,273.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, SVP Brian W. Ellis sold 4,000 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The shares were sold at an average price of $250.01, for a total value of $1,000,040.00. Following the transaction, the senior vice president now directly owns 29,830 shares of the company’s stock, valued at $7,457,798.30. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Rainer Blair sold 47,175 shares of Danaher stock in a transaction that occurred on Wednesday, April 24th. The stock was sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at $28,908,273.90. The disclosure for this sale can be found here. Insiders have sold 106,565 shares of company stock valued at $26,641,364 in the last quarter. Insiders own 11.10% of the company’s stock.

Danaher Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Thursday, March 28th were paid a $0.27 dividend. The ex-dividend date was Wednesday, March 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s payout ratio is currently 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.